Shore Clinical TMS

What Shore Clinical TMS does

Shore Clinical TMS & Wellness Center is a single-site interventional psychiatry practice headquartered at 2106 New Road #D8 in Linwood, New Jersey, founded in 2019 by Dr. Srisai Gowda. The practice operates as part of the Beacon Behavioral Partners network of physician-led psychiatric practices and positions itself as the first comprehensive interventional psychiatry clinic in the Jersey Shore area and the only New Jersey practice offering the full advanced-treatment stack (TMS, Spravato, IV ketamine, and medication management) under one roof.

The clinical model centers on neuromodulation and pharmacotherapy for treatment-resistant mental health conditions. Core technology includes MagVenture TMS devices for standard rTMS, two BrainsWay Deep TMS machines with both H1 (MDD) and H7 (OCD) helmets, Accelerated TMS using Theta Burst Stimulation, FDA-approved Spravato (esketamine) nasal spray, and IV ketamine infusion therapy delivered in private treatment rooms. These neuromodulation modalities are supported by traditional psychiatric services including medication management, psychotherapy, comprehensive psychiatric evaluations, and Genomind pharmacogenetic testing for personalized medication selection. The clinical team comprises two board-certified psychiatrists (Dr. Gowda and Dr. Moataz Hassan Ragheb), a PMHNP, a physician assistant, a therapist, and an RN with technicians.

Revenue is generated through recurring treatment courses reimbursed primarily via major commercial insurers (Aetna, Cigna, BCBS, Optum, UnitedHealthcare, AmeriHealth, TRICARE) and Medicare. Standard pricing is structured around multi-week protocols (e.g., 36 TMS sessions over 7-8 weeks; Spravato weekly then biweekly maintenance; ketamine infusion series). New patient acquisition relies on a multi-channel approach combining local SEO, content marketing, Google reviews, Zocdoc online scheduling, formal healthcare provider referrals, and telepsychiatry for remote consultations, with Medicaid explicitly excluded from accepted insurance.

Name

Shore Clinical TMS

Legal name

Shore Clinical TMS & Wellness Center

Website

https://shoreclinicaltms.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Shore Clinical TMS is a single-site interventional psychiatry practice in Linwood, New Jersey, offering TMS therapy, Spravato, IV ketamine, medication management, and psychotherapy to adults and adolescents with treatment-resistant depression, anxiety, PTSD, OCD, ADHD, and related conditions, reimbursed through major commercial insurers and Medicare.

Ownership category

akta.pro rank

Product category

Interventional Psychiatry / Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Psychiatry & Medication Management Platforms (HLALAEAB)

akta.pro secondary industry

Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ)

Keywords

• Interventional psychiatry
• Transcranial magnetic stimulation
• Treatment-resistant depression
• Esketamine nasal spray
• IV ketamine therapy

Headquarters

HQ city

Linwood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Psychiatric Services Revenue: Revenue generated from comprehensive psychiatric care services including evaluations, medication management, psychotherapy, and ongoing treatment sessions. Accepts most major insurance carriers including Medicare, Aetna, Cigna, Blue Cross Blue Shield, Optum, AmeriHealth, TRICARE, UnitedHealthcare, and others.
2. TMS Therapy Services: Transcranial Magnetic Stimulation therapy services including regular TMS (rTMS), Deep TMS, and Accelerated TMS. Standard course of 36 sessions over 7-8 weeks, with maintenance treatments available.
3. Spravato (Esketamine) Treatment: FDA-approved esketamine nasal spray treatment for treatment-resistant depression. Treatment protocol: 1-2x weekly for first month, weekly for second month, then biweekly maintenance. Administered under medical supervision in certified clinic.
4. IV Ketamine Therapy: IV ketamine infusion therapy for treatment-resistant conditions. Infusions last approximately 40-60 minutes, administered in private treatment rooms with medical monitoring.
5. Pharmacogenetic Testing: Genetic medication testing service in collaboration with Genomind, analyzing how patient genes affect medication response. Simple testing process with results typically within 24-72 hours of lab receipt.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Shore Clinical TMS & Wellness Center is an interventional psychiatry practice providing advanced neuromodulation and pharmacotherapy treatments for treatment-resistant mental health conditions. Core services include Transcranial Magnetic Stimulation (TMS) Therapy in standard, Deep TMS, and Accelerated variants, FDA-approved Spravato (esketamine) nasal spray, and IV ketamine infusion therapy. The practice complements these with traditional psychiatric services including medication management, psychotherapy, psychiatric evaluations, pharmacogenetic testing, and geriatric psychiatry, all delivered under one roof at their Linwood, NJ clinic.

Product overview

Shore Clinical TMS & Wellness Center is an integrated psychiatric practice offering a comprehensive suite of mental health treatment services centered around interventional psychiatry. The core offerings include Transcranial Magnetic Stimulation (TMS) Therapy in three variants (standard rTMS using MagVenture devices, Deep TMS via BrainsWay H-coil technology, and Accelerated TMS with Theta Burst Stimulation), combined with FDA-approved Spravato (esketamine) nasal spray and IV Ketamine infusion therapy. The practice complements these advanced neuromodulation treatments with traditional psychiatric services including medication management, psychotherapy, psychiatric evaluations, and pharmacogenetic testing (via Genomind partnership). As the only psychiatric practice in New Jersey offering all advanced treatment options under one roof, the integrated model allows for personalized, multi-modal treatment plans addressing conditions including treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, ADHD, and eating disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Transcranial Magnetic Stimulation (TMS) Therapy FDA-approved non-invasive neuromodulation therapy using gentle magnetic pulses to restore healthy function in brain mood centers. Offered in three variants: standard rTMS, Deep TMS using BrainsWay H-coil technology, and Accelerated TMS using Theta Burst Stimulation (TBS). Standard course consists of 36 sessions completed in about 7-8 weeks.
• Spravato (Esketamine) Treatment FDA-approved esketamine nasal spray for treatment-resistant depression, used alongside oral antidepressants. Targets NMDA receptors and the glutamate neurotransmitter system for rapid relief (within 24-48 hours) and enhanced neuroplasticity through BDNF release. Treatment protocol: 1-2x weekly for first month, weekly for second month, then biweekly maintenance.
• IV Ketamine Therapy Intravenous ketamine infusion therapy for treatment-resistant conditions. Delivers medication directly into the bloodstream for rapid relief of depressive symptoms, often within hours. Administered in private treatment rooms with 40-60 minute infusion times under medical monitoring.
• Psychotherapy Evidence-based talk therapy and counseling addressing mental health concerns including grief, relationship issues, family conflicts, and emotional challenges. Utilizes client-centered approach with personalized treatment plans.
• Pharmacogenetic Testing (Genomind) Genetic testing service analyzing how a patient's genes affect medication response, using the Genomind platform for predicting medication metabolism and response. Reduces trial-and-error in psychiatric medication selection. Performed via cheek swab or blood sample with results available within 24-72 hours of lab receipt.
• Medication Management Comprehensive psychiatric medication management including prescribing, monitoring, and adjusting medications. Covers antidepressants (SSRIs, SNRIs), mood stabilizers (Lithium, Depakote), antipsychotics, anti-anxiety agents, and stimulants for ADHD.
• Psychiatric Evaluations Comprehensive psychiatric evaluations for observing and diagnosing emotional, behavioral, or developmental disorders. Includes detailed assessment of circumstances, family history, substance use, development, medical history, and social experiences.
• Geriatric Psychiatry Mental health care for older adults addressing depression, anxiety, mood disorders, and cognitive challenges related to life transitions, medical conditions, and changes in independence. Integrates traditional psychiatric care with innovative interventional psychiatry approaches including medication management, Spravato, IV ketamine, and TMS therapy.

Quantifiable outcome

• Over 60% of TMS patients experience significant reduction in depression symptoms; one-third achieve full remission.
• +2 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• GenomindcoreTechnology or IntegrationGenomind is the industry leader in mental health medication gene testing. Shore Clinical TMS collaborates with Genomind for pharmacogenetic testing services, providing a simple testing process with rapid turnaround times (24-72 hours) and quality assurance through independent double-testing of every sample at their New York lab.
• Beacon Behavioral PartnersflagshipStrategic or Co-development PartnerBeacon Behavioral Partners drives a nationwide network of physician-led psychiatric practices. Shore Clinical TMS operates as part of the Beacon network, empowering growth and innovation in behavioral healthcare with a focus on patient care without barriers.
• ZocdoccoreChannel Partner/ Reseller/ DistributorZocdoc provides online scheduling platform enabling Shore Clinical TMS patients to book appointments directly through the Zocdoc platform. Practice is listed as Shore Clinical TMS and Wellness Center on Zocdoc with monolith provider ID 68659.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Others

• Headway: Network and software platform connecting patients with in-network mental health providers and helping clinicians with insurance credentialing. Ecosystem enabler comparable to Shore Clinical's payer-credentialed psychiatry model.

Broad incumbents

• Talkspace: Online therapy and psychiatry platform offering virtual mental health services including medication management. Adjacent incumbent providing competing outpatient mental health access, though not in-person interventional psychiatry.
• BetterHelp: Large online therapy network serving the same anxiety, depression, and behavioral health populations. Broad incumbent competitor in the outpatient mental health access market, though therapy-only without medication or neuromodulation.
• LifeStance Health: Large publicly traded outpatient mental health platform providing psychiatric evaluation, medication management, and therapy across hundreds of locations. Broader incumbent in the same outpatient psychiatry and behavioral health services market.

Direct peers

• Cerebral: Mental health platform offering online medication management and therapy for depression, anxiety, and ADHD. Comparable as a psychiatry-forward mental health provider focused on accessible medication management and online booking.
• Mindpath Health: Outpatient psychiatric and behavioral health practice group offering medication management, therapy, and interventional treatments including TMS. Comparable multi-provider psychiatric practice model with insurance contracting and TMS capabilities.
• Greenbrook TMS: Multi-site TMS therapy provider offering transcranial magnetic stimulation for depression and OCD. Directly comparable as a dedicated interventional psychiatry operator using BrainsWay and other TMS devices across a clinic network.
• Talkiatry: National telepsychiatry and in-person psychiatry platform providing medication management and psychiatric evaluations. Directly comparable as a psychiatry-led practice model focused on medication management for common and treatment-resistant mental health conditions, with strong insurance contracting.
• Pasithea Clinics: Specialty clinic chain offering IV ketamine infusion therapy for treatment-resistant mental health conditions. Directly comparable as a ketamine-focused interventional psychiatry operator targeting the same treatment-resistant depression population.

Emerging players

• KetaMD: Telehealth ketamine provider offering at-home ketamine-assisted treatment for mental health conditions. Emerging player intersecting with Shore Clinical's IV ketamine offering via a different delivery model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC9b1YF7D6_kX5U6JVl40iBQ
• Facebookfacebook.com/ShoreClinicalTMS
• LinkedInlinkedin.com/company/shore-clinical-tms
• Instagraminstagram.com/shoreclinicaltms

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shore Clinical TMS